论文部分内容阅读
目的:观察中医药综合治疗对中晚期非小细胞肺癌(NSCLC)化疗后患者生活质量及无进展生存期的影响。方法:将70例中晚期NSCLC患者随机分为对照组和观察组各35例。对照组在一线化疗方案结束采用西医常规对症支持治疗,随访直至出现病情进展后终止观察;观察组采用静脉滴注黄芪多糖250 mg及扶正消积方内服维持治疗,并随访患者至病情进展。记录2组无进展生存期,治疗前后KPS评分及生命质量核心量表(EORTCQLQ-C30)评分。结果:治疗后观察组KPS评分提高加稳定率85.71%,优于对照组42.85%(P<0.01);治疗后观察组躯体功能、角色功能、情绪功能、社会功能和整体生活质量评分均高于对照组(P<0.01);治疗后观察组疲倦、疼痛、恶心与呕吐、呼吸困难、失眠、食欲丧失、便秘、腹泻评分均较治疗前下降(P<0.01,P<0.05),并低于对照组(P<0.01);观察组无进展生存期(7.1±0.8)月,优于对照组的(4.3±1.4)月(P<0.01)。结论:中医药综合治疗能提高化疗后中晚期NSCLC患者的生存质量,减轻临床临床症状,延长无进展生存期。
Objective: To observe the effect of traditional Chinese medicine (TCM) on quality of life and progression-free survival in patients with advanced non-small cell lung cancer (NSCLC) after chemotherapy. Methods: Seventy patients with advanced NSCLC were randomly divided into control group and observation group of 35 cases. Patients in the control group were treated with conventional symptomatic supportive therapy of western medicine at the end of the first-line chemotherapy regimen and were followed up until the progression of the disease was observed. The observation group was treated with intravenous infusion of Astragalus polysaccharide 250 mg and Fuzheng Xiaoji Decoction orally. The patients were followed up until the disease progressed. Two groups of progression-free survival, before and after treatment KPS score and quality of life core scale (EORTCQLQ-C30) score. Results: After treatment, the KPS score of the observation group was 85.71%, which was significantly higher than that of the control group (42.85%, P <0.01). After treatment, the body function, role function, emotional function, social function and overall quality of life in the observation group were higher than those in the control group (P <0.01). After treatment, the scores of fatigue, pain, nausea and vomiting, dyspnea, insomnia, loss of appetite, constipation and diarrhea in observation group after treatment were significantly lower than those before treatment (P <0.01, P < (P <0.01). The progression-free survival (7.1 ± 0.8) months in the observation group was better than that in the control group (4.3 ± 1.4) months (P <0.01). Conclusion: The comprehensive treatment of traditional Chinese medicine can improve the quality of life of patients with advanced NSCLC after chemotherapy, relieve the clinical symptoms and prolong the progression-free survival.